iBio, Inc.
IBIO
$4.51
-$0.35-7.20%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 650.00% | 250.00% | -- | -- | -97.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 650.00% | 250.00% | -- | -- | -97.22% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 650.00% | 250.00% | -- | -- | -97.22% |
| SG&A Expenses | -15.29% | -37.46% | -38.61% | -49.18% | -49.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.33% | -41.13% | -42.55% | -47.63% | -44.21% |
| Operating Income | 24.95% | 41.67% | 43.31% | 47.78% | 41.51% |
| Income Before Tax | 31.48% | 46.52% | 47.31% | 50.73% | 41.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.48% | 46.52% | 47.31% | 50.73% | 41.04% |
| Earnings from Discontinued Operations | 22.15% | 65.89% | 73.49% | 85.38% | 85.81% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.25% | 56.01% | 61.69% | 69.54% | 66.37% |
| EBIT | 24.95% | 41.67% | 43.31% | 47.78% | 41.51% |
| EBITDA | 25.82% | 43.07% | 45.11% | 49.67% | 43.27% |
| EPS Basic | 90.12% | 92.73% | 91.39% | 89.28% | 84.56% |
| Normalized Basic EPS | 89.45% | 89.64% | 85.09% | 81.36% | 72.03% |
| EPS Diluted | 90.11% | 92.73% | 91.39% | 89.28% | 84.56% |
| Normalized Diluted EPS | 89.45% | 89.64% | 85.09% | 81.36% | 72.03% |
| Average Basic Shares Outstanding | 557.65% | 610.92% | 526.76% | 276.08% | 153.31% |
| Average Diluted Shares Outstanding | 557.65% | 610.92% | 526.76% | 276.08% | 153.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
